A scientist prepares protein samples for analysis in a lab at the Institute of Cancer Research in Sutton, Britain, July 15, 2013. (Stefan Wermuth)
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Only about half of the cancer drugs approved by the European Medicines Agency in the last few years were later shown to help patients live longer or improved their lives, a new study says.Many regulators, including the U.S. Food and Drug Administration, often OK drugs based on initial surrogate measures because it can take many years before solid data about the drugs' effectiveness exists.Among the drugs that were shown to help patients were 23 cancer medicines including Herceptin, often used to treat breast cancer, and Zytiga for prostate cancer.For other drugs, however, researchers often found that when they extended survival they were often "marginal". Rose Gray, a senior policy adviser at the British charity Cancer Research UK, said the trend toward personalized medicine in cancer could make gathering large amounts of data about drugs' effectiveness challenging, since these treatments often target small groups of patients with certain genetic traits.But she said that even though many new drugs may only extend patients' lives a few weeks or months, such gains can be worthwhile.
FOLLOW THIS ARTICLE